Med24
clinical-research 20. 10. 2026 • 2 min read • ClinicalTrials.gov (National Cancer Institute (NCI))

A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This pilot phase I trial investigates the safety of atezolizumab (MPDL3280A) in patients with cancer undergoing adoptive cell transfer (ACT). The study enrolls 40 participants with Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, or Unresectable Malignant Solid Neoplasm.

Study Procedures and Assessments

Participants receive atezolizumab intravenously (IV) over 30-60 minutes, repeated every 21 days for a total of 17 doses up to 12 months, contingent on the absence of disease progression or unacceptable toxicity. During the study, patients undergo computed tomography (CT) and magnetic resonance imaging (MRI) scans. They also undergo tissue biopsies and blood specimen collection for laboratory biomarker analysis and correlative studies.

Sponsored content

Efficacy and Follow-up

The study aims to evaluate the safety of atezolizumab administration following ACT. Secondary objectives include assessing the expansion of engrafted T cells in the peripheral blood and tumor microenvironment, evaluating the phenotype and function of these T cells, observing anti-tumor activity, and evaluating response rates using immune-related Response Criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, or other tumor-specific criteria. Furthermore, the study will evaluate survival outcomes and progression-free survival using irRC and RECIST v1.1, or other tumor-specific criteria. Following treatment completion, patients are followed up at 4 weeks, 8 weeks, and then every 3 months thereafter.

Original Scientific Source
ClinicalTrials.gov (National Cancer Institute (NCI))
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement